Sildenafil for Primary Prevention of Anthracycline-Induced Cardiac Toxicity: A Phase I/II Randomized Clinical Trial, SILDAT-TAHA6 Trial

BACKGROUND: Previous animal studies have shown a protective effect of 5-phosphodiesterase inhibitors on cancer therapeutics-related cardiac dysfunction (CTRCD) of anthracyclines. AIM: The aim of this study was to evaluate the clinical effect of sildenafil on the primary prevention of CTRCD in human....

Descripción completa

Detalles Bibliográficos
Autores principales: Attar, Armin, Heydari, Masoumeh, Abtahi, Firoozeh, Rezvani, Alireza, Haghighat, Shirin, Vojdani, Reza, Ramzi, Mani, Dehghani, Mehdi, Karimi, Mojtaba, Kasaei, Mohammad, Khosropanah, Shahdad, Tabandeh, Mahmood
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977337/
https://www.ncbi.nlm.nih.gov/pubmed/35387238
http://dx.doi.org/10.1155/2022/5681510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977337/
https://www.ncbi.nlm.nih.gov/pubmed/35387238
http://dx.doi.org/10.1155/2022/5681510

Ejemplares similares